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Abstract
Background: Gastric cancer metastasis is a highly fatal disease with a five-year survival rate of less than 5%. One major
obstacle in studying gastric cancer metastasis is the lack of faithful models available. The cancer xenograft mouse
models are widely used to elucidate the mechanisms of cancer development and progression. Current procedures for
creating cancer xenografts include both heterotopic (i.e., subcutaneous) and orthotopic transplantation methods.
Compared to the heterotopic model, the orthotopic model has been shown to be the more clinically relevant design
as it enables the development of cancer metastasis. Although there are several methods in use to develop the
orthotopic gastric cancer model, there is not a model which uses various types of tumor materials, such as soft tissues,
semi-liquid tissues, or culture derivatives, due to the technical challenges. Thus, developing the applicable orthotopic
model which can utilize various tumor materials is essential.
Results: To overcome the known limitations of the current orthotopic gastric cancer models, such as exposure of
tumor fragments to the neighboring organs or only using firm tissues for the orthotopic implantation, we have
developed a new method allowing for the complete insertion of soft tissue fragments or homogeneously minced
tissues into the stomach submucosa layer of the immunodeficient NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mouse. With
this completely-closed transplantation method, tumors with various types of tissue may be used to establish
orthotopic gastric cancer models without the risks of exposure to nearby organs or cell leakage. This surgical procedure
was highly reproducible in generating forty-eight mouse models with a surgery success rate of 96% and tumor
formation of 93%. Among four orthotopic patient-derived xenograft (PDX) models that we generated in this study, we
verified that the occurrence of organotropic metastasis in either the liver or peritoneal cavity was the same as that of
the donor patients.
Conclusion: Here we describe a new protocol, step by step, for the establishment of orthotopic xenograft of gastric
cancer. This novel technique will be able to increase the use of orthotopic models in broader applications for not only
gastric cancer research but also any research related to the stomach microenvironment.
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Background
Gastric cancer is the fourth most common cancer in the
world and the second leading cause of cancer-related
death worldwide [1–3]. Although chemotherapy has been
proven as a standard of care for stage IV gastric cancer
[4], the 5-year survival rate of advanced gastric cancer re-
mains at 5–10% [5–7]. Patients with distant metastasis
have a particularly poor prognosis, less than 5% survival
rate after 5-years, and for these patients, curative surgical
resection is no longer an option [6, 8]. Gastric cancer
commonly metastasizes to the liver, peritoneum, lymph
nodes, lung and bone. The liver is the most common dis-
tant metastasis site with a survival rate of 33% at 1-year [9,
10]. The proportion of gastric cancer patients with metas-
tases has grown from 24 to 44% over a 20–year period,
showing an urgent need for an optimized approach for
both treatment and diagnosis [11]. Due to the high hetero-
geneity of gastric cancer and the lack of faithful experi-
mental models, the mechanism of gastric cancer
metastasis is still largely unknown [12, 13].
Cancer xenograft mouse models are utilized broadly to
understand cancer biology and to determine the
pharmacological activities of therapeutic agents for
therapy development [14–16]. When developing a new
mouse model, the transplantation site is the most critical
and influential factor affecting tumor initiation, prolifer-
ation, and metastasis [17–20]. The heterotopic or ec-
topic engraftment, when cancer cells or tissues are
transplanted into the subcutaneous area of the mouse
flank or dorsal regions, is the most commonly used in
establishing cell line-derived xenografts (CDXs) or
patient-derived xenografts (PDXs) because it is both easy
to generate the models and to monitor the tumor vol-
ume [21]. However, the heterotopic transplantation site
does not provide the crucial microenvironment of the
organ where the tumor developed in the patient [22–
24]. Indeed, for some tumor types such as colorectal
cancer, the subcutaneous model is shown to have a
lower engraftment rate than that of the orthotopic
model, which provides a better likelihood of tumor
settlement in the mouse environment [17, 18]. Orthoto-
pic tumor xenografts are utilized to study metastasis of
various tumor types and are proved to be one of the best
experimental models to represent the spontaneous me-
tastasis mechanisms [24, 25]. To study gastric cancer
metastasis, several orthotopic transplantation methods
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have been developed. However, each has significant
weaknesses which limit its broad use (Table 1); (1) The
single-cell suspension injection method is not usable to
engraft tissues [26], (2) Tissue transplantation by stitch-
ing onto the exposed subserosa of the stomach is a rela-
tively simple method, however, the transplanted tumor
tissue is exposed to the peritoneal cavity which can in-
crease the chance of adhesion to neighboring organs.
Moreover, only firm tissue fragments can be affixed to
the surface with a suture [27], and (3) Tissue transplant-
ation into the subserosa using tissue glue can be
achieved by inserting only a firm, ≤ 1mm3 tissue frag-
ment through a cut in the serosa then covering the
opening with tissue glue to prevent tissue re-emergence
and exposure to nearby organs. The exceptionally small
size of fragment does not allow recapitulation of hetero-
geneity of the tumor [28]. There are methods for trans-
planting tissues orthotopically into the mouse stomach,
however, none of them allow for complete insertion into
the stomach wall, which is too thin for tissue fragment
transplantation. In order to overcome the weaknesses of
the current methodologies, we have developed a novel
orthotopic transplantation method of gastric cancer,
which permits the transplantation of various gastric
cancer-derived materials without encountering the prob-
lems associated with exposure to neighboring organs or
the peritoneal cavity (Fig. 1). Briefly, in the subserosa re-
gion of the stomach, a space is created by injecting a low
concentrated matrigel solution or saline, the tumor is
then transplanted into that space. Following tumor
transplantation, the entry of the implantation site is
closed thoroughly by compression with a sterile swab.
This new orthotopic method, where the stomach tumor
forms at the implantation site, most closely resembles
tumor development shown in patients. Although ad-
vanced surgical techniques may be required, this proced-
ure can be utilized to generate a proper experimental
model for multiple research purposes; a model which
more accurately mirrors the human patient. In this re-
port, we describe in detail the preparation and surgical
A a b
B







Fig. 1 The procedures for the completely-closed orthotopic transplantation of gastric cancer in NSG mice. A. a. Skin incision made using iris scissors. b. Exposing
the stomach. Retractors hold both the skin and abdominal walls while forceps gently grab the stomach. B. A syringe assembly using an 18 gauge blunt needle
and filled with homogenous minced tumor tissue. C. a. Injection of a low concentration of matrigel. b. Widening the entry to the space created under the serosa
layer. c. Transplantation of up to 20ul of homogenous minced tissue. d. Tumor completely loaded into the stomach wall without leakage. D. a. Injection of a low
concentration of matrigel. b. Widening the entry to the space created under the serosa layer. c. Transplantation of a 3mm diameter fragment of soft tumor d.
The tumor tissue completely inserted into the stomach wall without exposure. E. a. The abdominal wall closure with suture. b. The skin closed with wound clips.
F. An illustration of the properly positioned transplantation site of the completely closed implantation method
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procedures of a novel orthotopic transplantation
method. We also present the incidence of metastasis and
metastatic organ preference shown by four different gas-
tric cancer PDX models which were established using
this novel methodology.
Results
The present study aims to develop a new method that
enables transplantation of various types of materials de-
rived from gastric tumors into the mouse stomach in
order to overcome the existing shortcomings of orthoto-
pic methods and also to assess the clinical reliability of
the orthotopic gastric cancer model.
Establishment of the Orthotopic Gastric Cancer
PDX Model by Using the Completely-Closed
Transplantation Method
The procedures described in the method section are the
preparation of a homogenous minced PDX tumor and
as well as a protocol for micro-surgery. Tumors from
patients who developed gastric cancer liver metastasis or
peritoneal metastasis were selected to evaluate the meta-
static potential and clinical relevance of the orthotopic
model. We chose subcutaneous tumors of four gastric
cancer PDX models: SNU-JAX-G364, SNU-JAX-G439,
SNU-JAX-G440 and SNU-JAX-G127, which had been
established at Seoul National University (SNU) Hospital
and Cancer Research Institute, SNU College of Medicine
(Seoul, Korea) by collaborating with The Jackson La-
boratory for Genomic Medicine (CT, USA). The SNU-
JAX-G364 model is a PDX transplanted stomach tumor
derived from a patient who developed liver metastasis
after primary tumor removal. Both SNU-JAX-G439 and
SNU-JAX-G440 are PDXs transplanted liver metastasis
that were biopsied from gastric cancer patients. Lastly,
the SNU-JAX-G127 model is a PDX transplanted lymph
node metastasis derived from a gastric cancer patient
who developed peritoneal metastasis. Importantly, trad-
itional subcutaneous methods of these four PDX models
have not demonstrated the development of metastatic
tumors in mice. The PDX tumors which were passaged
twice subcutaneously using NSG mice were prepared for
transplantation following Protocol #1 or #2. Depending
upon the experimental goals, either cryopreserved or
fresh tumors can be transplanted using the proposed
methodology. We used PDX tumor freshly harvested
from the previous passage in order to reduce any varia-
tions between the tumor growth rate in the same group
due to the thawing-recovery process.
Since the mouse stomach wall thickness is only ~ 0.5
mm, the surgical site was fortified by creating an en-
larged space between the serosa and muscle wall by
using a 50% mixture of matrigel with RPMI media, the
same media used to ship or store patient or PDX tu-
mors. We used the dilute matrigel to enhance tumor set-
tling and maintain the space for ease of transplantation,
however, saline may be used as an alternative reagent. In
total, 48 orthotopic mice models were generated from
the four PDX models (n = 8–14 for each model). Post-
surgery, two mice did not recover from anesthesia,
which gives a surgical success rate of 96%. Tumor for-
mation at the transplantation site was confirmed in
forty-four out of forty-six implanted mice, which sets
the transplantation success rate at 96% (Fig. 2). From in-
cision to closure, the average time of surgery was 15 min
per mouse. At 3 weeks post-surgery, a mouse was sacri-
ficed and the orthotopic transplantation site was ob-
served by macroscopic and microscopic examination to
PDX Tumor site
Mouse #



























Fig. 2 The occurrence of primary and metastatic tumors in gastric cancer orthotopic PDXs. The compiled data of stomach tumor formation
(yellow box) determined the transplantation rate of each PDX model. The red or blue box indicates that either liver metastasis or peritoneal
seedings occurred in mice, respectively. Green indicates that the mouse developed metastatic tumors at other distant organs than that which
occurred in the donor patients, and, in this case, it was the ovary in the SNU-JAX-G440 model
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evaluate both the shape and potential leakage of the
tumor. We found that the tumor stayed in the subserosa
area and no evidence of leakage was seen (Fig. 3A). Also,
the vascular formation was actively progressing around
the tumor, which could support tumor settlement and
proliferation. Histological observation showed that can-
cer cells that were positive for Ki-67 expression, a prolif-
erative cell marker, invaded into the mucosa layer,
which proved the tumor was spreading through stomach
layers. Compared to the stomach from a normal NSG
mouse, the submucosal region of the PDX stomach was
observed as being significantly occupied by the prolifer-
ating tumor (Fig. 3B).
Stomach Tumor Formation and Metastasis in the
Orthotopic PDX Models
All mice were monitored twice a week until tumor
growth was observed in the stomach. Since we did not
utilize an in vivo imaging system, the tumor formation
was traced by palpating the abdominal area gently and
checking for other physical symptoms (e.i., ascites).
When tumor formation was found or suspected, the
mice were monitored daily. During the experiments, if
mice exhibited any abnormal symptoms, such as weight
loss of more than 20%, or gain of more than 20% due to
the formation of ascites or tumors, or body condition
score (BCS) of equal to or less than 2 [29], they were im-
mediately euthanized. The median experimental days for
confirmation of tumor formation in the orthotopic
models of SNU-JAX-G364, SNU-JAX-G439, and SNU-
JAX-G440 was 58 days (range: 23–153 days), 50 days
(range: 35–138 days), and 41 days (range: 34–83 days)
post-trans-plantation, respectively. Additionally, the me-
dian survival was 124 days (range: 56–183 days), 116 days
(range: 66–180 days), and 100 days (range: 70–148 days)
post-transplantation in the orthotopic models of SNU-
JAX-G364, SNU-JAX-G439, and SNU-JAX-G440, re-
spectively. These PDX models resembled the metastatic
patterns shown in the donor patients. The orthotopic
models of SNU-JAX-G364, SNU-JAX-G439, and SNU-
JAX-G440 developed liver metastasis with incidences of
17, 92, and 25%, respectively. The differences in the
metastatic capacity among PDX models may be a result
of diversity in the metastatic mechanisms, tumor hetero-
geneity, and/or the observation time point in our study
[30–36]. The liver metastasis in the three donor patients
of these PDX models was diagnosed after stomach
tumor removal. We euthanized those mice with stomach
tumors and then post-mortem observed the metastatic
sites. The metastatic capacity may be different among
models depending upon the aggressiveness of the stom-
ach tumor and metastasis process at the observation
point. The incidence of metastasis may increase if we
were able to apply a gastrectomy removing the stomach
tumors in mouse models as in the patients’ cases, then
this would allow us to further monitor the models until
metastasis occurred. The liver was a dominant organ of
metastasis in these models, with the exception of ovary
metastasis which developed in two out of the twelve
mice in the SNU-JAX-G440 group (Fig. 2). Peritoneal
metastasis occurred in all of the SNU-JAX-G127 ortho-
topic model mice.
The tumors of these PDX models conserved the iden-
tical histological features of donor patients’ original tu-
mors (Fig. 4). The tumor pathology of both the PDXs
and the patients was solid type poorly differentiated
adenocarcinoma for SNU-JAX-G364 and SNU-JAX-
G127, poorly cohesive carcinoma with signet ring cell
component for SNU-JAX-G440, and intestinal-type well-
differentiated adenocarcinoma for SNU-JAX-G439.
All PDX tumor harvests and subsequent implantation
into the recipient mouse were performed on the same
day; while awaiting surgical implantation all tissues were
stored on ice. The orthotopic models were generated se-
quentially from the first mouse (#1) to the last in each
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Fig. 3 The macro and micro-morphology of the stomach tumor three weeks post transplantation. A. The tumor location under the serosa layer
of the stomach. B. Images of the stomach tumor transection. a. A low magnification H&E. b. Ki-67 IHC. The regions indicated by the box were
magnified to focus on the mucosa and submucosa layers of the stomach. c. A high magnification H&E and d, Ki-67 IHC. The last two images
show a healthy mouse stomach with, e. H&E and f, Ki-67 IHC. The equal-height bracket indicates the thickness of the mucosa layer in each image
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the occurrence rate of metastasis among mice due to a
variation in tissue transplantation time (Fig. 2). Stomach
tumors were large enough to attach to the liver, how-
ever, there was no direct invasion of the tumor into the
liver parenchyma. The liver metastatic tumors were
found in lobes distant from the stomach and were har-
vested to investigate the histological morphology. Each
model exhibited different features of metastatic patterns.
The SNU-JAX-G364 liver metastatic tumor was a large
mass in the liver which overwhelmed the hepatocytes
and normal hepatic structures. The SNU-JAX-G439
orthotopic model showed the highest incidence of ex-
tremely invasive liver metastasis. The livers with meta-
static tumors were fragile and had lesions of various
colors, such as yellow, dark green, black, and white, sug-
gesting that there might be severe damage to the normal
function of the liver. In the gross examination, the SNU-
JAX-G440 mice had only small tumor masses in the liver
without any other abnormality. However, many micro-
metastatic tumors were observed in the H&E images
(Fig. 5). The SNU-JAX-G127 orthotopic model devel-
oped hemorrhagic ascites along with cancer cell seeding
in mesenteric sites and organs, including kidney, intes-
tines, or ovary in the peritoneal cavity (Fig. 6). The me-
dian experimental day of tumor formation confirmation
was 39 days (range: 35–41 days) post-transplantation and
the median survival was 72 days (range: 58–106 days)
post-transplantation in the orthotopic models of SNU-
JAX-G127.
Discussion
Despite the critical need to find the optimal strategy for
diagnosis and treatment of gastric cancer metastasis, the
paucity of reliable translational animal models is a huge
impediment to investigating this disease. We have estab-
lished a novel method which enables the transplantation
of a multitude of tissue types into the stomach orthoto-
pically. Both the advantages and limitations of this new
approach, a completely-closed implantation method,
were compared with other commonly used methods in
Table 1. There are several crucial points to consider to
conduct a successful procedure. Firstly, in order to pre-
vent severe dehydration or hypothermia and ensure the











Fig. 4 The similarity of tumor pathology between the PDX models and the original patients. The H&E image of A. SNU-JAX-G364 PDX tumor, B.
SNU-JAX-G364 original tumor, C. SNU-JAX-439 PDX tumor, D. SNU-JAX-439 original tumor, E. SNU-JAX-440 PDX tumor, F. SNU-JAX-440 original
tumor, G. SNU-JAX-127 PDX tumor, and H. SNU-JAX-127 original tumor (X100, Scale bar = 200 μm
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organs must be kept hydrated by covering with wet
gauze or supplying warm sterile saline, and the body
temperature must be maintained by using an appropriate
warming pad. Secondly, the duration of surgery is a fac-
tor which influences the achievable scale of an experi-
ment, as well as the success of each surgery. In order to
minimize the critical surgical time, it is important to
work as a team with staff both monitoring mouse recov-
ery and supporting the surgery. Thirdly, the most critical
and challenging step in this model is creating a space by
injection of solution just below the serosa. It requires ex-
tensive practice to ensure both correct placement and
repeatability. If injection of the solution is too deep into
the muscular layer or submucosal layer, pillar structures
of connective tissue may form inside the space and ob-
struct transplantation of tissue. Fourthly, adding the
matrigel to the tumor materials may be beneficial to
complete this procedure. Matrigel is a well-known gelat-
inous protein mixture consisting of extracellular matrix
substrates and is used to increase engraftment rate in
PDX models [37]. In our study, matrigel might support
the stabilization of the homogenous minced tumors in
the transplantation site by its characteristic transform-
ation into a gel when responding to body temperature.
This transformation provides a less fluidic-matrix which
may support the prevention of leakage of tumors from
the injection site during the procedure, helping to ac-
complish complete closure of the transplantation site.
Lastly, complete closure of the transplantation site is es-
sential to prevent the leakage which causes adhesion to
neighboring organs or to the incision on the abdominal
wall. Although we found that with slight pressure from a
swab on to the injection site, complete-closure was
achieved, as a supplementary material, a tissue adhesive
can be applied to seal the site completely, and the gel-
foam, also, can be used to cover the entry of the trans-
plantation area. In this study, we observed stomach





























Fig. 5 The macro and micro-morphology of the stomach tumor and liver metastasis. The white dotted lines show transplanted cancer cells which
grew in each stomach. The black arrow bar on the H&E images of the stomach tumor indicate the region of tumor mass in the submucosa area. Gross








Fig. 6 The stomach tumor and peritoneal metastasis in the SNU-JAX-G127 orthotopic model. A. The SNU-JAX-G127 orthotopic mouse developed
hemorrhagic ascites. The tumor mass was visible and palpated through the abdominal wall. B. a. The white dotted line outlines where the tumor
mass grew in the stomach. b, and c. Small tumor nodules are shown in the peritoneal cavity and mesenteric areas. d. The liver presents without
tumor or abnormality. C. a. The H&E image of tumor modules seeded in the peritoneal cavity and b, mesenteric area
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after the animal was sacrificed, but with the use of im-
aging equipment, such as small animal magnetic reson-
ance imaging (MRI) or ultrasound, we will be able to
investigate the complex cascades of gastric cancer me-
tastasis, created by applying various types of tumor ma-
terials, in living animals. Furthermore, the genes
responsible for the liver metastasis of gastric cancer will
be further studied and functionally validated by utilizing
the metastatic tumors and the primary stomach tumors
from each PDX model we have developed in this study.
Conclusions
Existing orthotopic implantation methods of the
stomach tumor are used to generate the orthotopic
gastric cancer models to study cancer biology and/or
metastasis. However, due to technical difficulties, only
specific types of material have been able to be trans-
planted, such as single-cell suspension or a firm frag-
ment of tumor [26–28]. Our study reports a novel
surgical procedure that is able to overcome the weak-
nesses of the existing methodologies. Although this
new method may require a higher level of surgical
skill than the others, it will generate a reliable and
consistent orthotopic model that transplants an equal
amount of either homogeneously minced tissue or
other soluble tissue materials. Potentially, this novel
completely-closed transplantation method can be used
for investigating the functions of biomarkers, testing
the efficacy of antitumor or anti-metastatic drugs, and
be utilized for more broad applications such as stud-
ies employing gastric cancer organoids, or non-
cancerous materials that relate to the stomach
microenvironment.
Methods
Protocol #1. Preparation of Fresh Homogeneous Minced
Tumor
1. All procedures are performed in the biosafety
cabinet.
2. The tumor tissue is washed with cold phosphate-
buffered saline (PBS) and placed in a petri-dish,
which is sitting on an icepack. It is then minced
using surgical forceps and sterile single edge razor
blades into tiny fragments that are less than 1 mm
diameter.
3. During the preparation of minced tumor materials,
a 50% matrigel solution diluted with RPMI 1640
media is added to the tumor matrix to avoid drying
of the tissues. As a tumor contains some amount of
the fluids in it, the supplementary solution volume
can be adjusted considering homogenous of the
tumor matrix. In this study, we applied the diluted
matrigel about 10–20% of tumor volume.
4. To prevent bubble formation in the minced tissues,
the tumor matrix is loaded through the plunger end
of a 5 ml syringe using surgical forceps. Any air is
forced out after applying pressure with the plunger.
Using this 5 ml syringe, the bubble-free tumor
matrix is introduced into a disposable 1 ml syringe,
which is then assembled with an 18 gauge needle
and stored on ice until use (Fig. 1B).
Protocol #2. Preparation of Soft Tumor Fragment
1. All procedures are performed in the biosafety
cabinet.
2. After washing with cold PBS, the tissue fragment is
placed in a Petri dish sitting on an icepack. Using
surgical forceps and sterile single edge razor blades,
the tissue is divided into small fragments (3X3X3
mm3).
3. An optimal soft tumor fragment is selected for
transplant and is placed in 200ul, 50% matrigel
solution diluted with RPMI 1640 media and stored
on ice until use.
Protocol #3. Creation of a Void in the Stomach Wall
1. All procedures are performed in the biosafety
cabinet in the Biosafety Label 2 (BSL2) procedure
room of the animal facility at UConn Health. All
work follows the animal protocols approved by
both the Institutional Animal Care and Use
Committee (IACUC) of UConn Health and The
Jackson Laboratory (#101660–0920 and #17065,
respectively).
2. The bodyweight of an 8 weeks-old, female NSG
mouse is measured and then is anesthetized by
intraperitoneal (IP) injection of 100 mg/kg ketamine
mixed with 10 mg/kg xylazine. An analgesic is also
given IP pre-surgery (Ketoprofen, 5 mg/kg) and all
are administered using disposable 1 ml syringes.
3. The mouse is placed on the mouse warming pad for
pre-operative preparation.
4. The fur of the region from the ventral abdomen
and the left flank, in an area bounded to the mid
thorax and pelvis, is removed using clippers. The
fur removal area can be extended to the dorsal
midline to remove the fur of the left dorsal region.
5. Loose fur is removed with adhesive tape, dry gauze
or gauze slightly dampened with ethanol.
6. Ophthalmic ointment is placed on the eyes to
prevent drying of the cornea.
7. The skin is disinfected with both 70% ethanol
and chlorhexidine using sterile swabs. The
application of 70% ethanol starts in the center of
the proposed incision site and works outward in
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ever-widening circles to cover the entire clipped
area, and then using a new sterile swab, repeat
again. Chlorhexidine is applied in the same
manner.
8. To keep the body temperature during the surgery, a
mouse warming pad, of which size fits for the
microscopic surgery, is placed under the surgical
microscope and covered by a sterile disposable
drape.
9. The mouse is placed in a dorsal recumbent position
under the surgical microscope and a sterile
Invisishield Aperture Surgical Drape is positioned
over the surgical site.
10. Using either Von Graefe Iris Forceps or Extra Fine
Graefe Forceps and Iris Scissors, a 2.0 cm skin
incision is made immediately caudal and parallel to
the caudal most rib (Fig. 1Aa).
11. The underlying muscle is incised and held by
retractors exposing the stomach (Fig. 1Ab) using a
fresh set of Von Graefe Iris Forceps or Extra Fine
Graefe Forceps and Iris Scissors.
12. Ring Forceps are used to hold the stomach in place
during the surgery. A moistened gauze can be used
to position the stomach exposing the greater
curvature of the glandular portion of the stomach.
13. For each animal one 31 gauge insulin syringe
containing dilute matrigel of sterile saline is
prepared and stored on ice until used.
14. In order to prepare a space for tissue
implantation, using a 31 gauge needle on an
insulin syringe 30–40 ul of either 50% matrigel
diluted with RPMI media or sterile saline is
injected into the subserosa area of the stomach
(Fig. 1Ca and Fig. 7B).
15. The serosa over the injection site is incised 2–3 mm
with Vannas Iridocapsulotomy Scissors in order to
evacuate all of the space-creating 50% matrigel or










Fig. 7 The procedure to transplant the homogeneous tissues under the stomach serosa layer. A. The layers compose the stomach wall. B. Using
a 31 gauge needle on an insulin syringe 30–40 ul of either 50% matrigel diluted with RPMI media or sterile saline is injected into the subserosa
area. C. The serosa over the injection site is incised 2–3 mm with Vannas Iridocapsulotomy Scissors in order to generate the entrance to insert the
18 gauge need and evacuate the space-creating 50% matrigel or saline. D. The solution which had leaked is wiped with sterile gauze or cotton
swabs. E. A cutting site is widened using Micro-Blunted Tip Dumont Forceps or Moria Iris Forceps. F. An 18 gauge needle is placed into the
inner-space. G. Fill the tissue slowly from the opposite area of the entrance. H. After implantation, the entry site is pressed lightly with a sterile
cotton swab and the needle is gently removed. I. Giving an extremely light and gentle pressure the transplantation site to confirm the leaking
and the entry site is pressed with a sterile cotton swab for 20–30 s, on average, until it closes completely. J. As an auxiliary closure, tissue adhesive
is beneficial to cover the incision site of the stomach serosa
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which had leaked is wiped with sterile gauze or
cotton swabs (Fig. 7D).
Protocol #4. Transplantation of Homogenous Minced
Tumor
1. Using Micro-Blunted Tip Dumont Forceps or
Moria Iris Forceps (Fig. 7E), a cutting site is wid-
ened in order to place an 18 gauge needle into the
inner-space (Fig. 7F) and inject up to 20 ul of tissue
(Fig. 1Cc and Fig. 7G).
2. After slow implantation, the needle is gently
removed (Fig. 7H) and the entry site is pressed
lightly with a sterile cotton swab for 20–30 s until it
closes completely. Giving an extremely light and
gentle pressure the transplantation site might help
to confirm whether there is anything leaking from
it. (Fig. 1Cd and Fig. 7I).
3. As an auxiliary closure, tissue adhesive or gelfoam
can be used to cover the incision site of the
stomach serosa (Fig. 7J).
Protocol #5. Transplantation of a Soft Tumor Fragment
1. Using Micro-Blunted Tip Dumont Forceps or
Moria Iris Forceps the transplant site is opened
gently (Fig. 1Db).
2. Dumont Forceps are used to insert the edge of the
tissue fragment into the incision site (Fig. 1Dc).
3. The tissue is gently pushed into the pocket until
completely inserted and then by nudging it through
the surface of the serosa, it is positioned at the far
end of the space opposite to the entry (Fig. 1Dd).
4. The incision site is closed by applying gentle
pressure with a sterile cotton swab.
Protocol #6. Closure of the Surgical Site And Animal
Recovery
1. After observing there is no leakage, the stomach is
gently advanced away from the opening.
2. The incision in the abdominal wall is closed with a
5–0 or 6–0 absorbable suture with a swaged on the
needle using Micro Needle Holders (Fig. 1Ea).
3. 0.1% bupivacaine is applied to edges of the skin
incision.
4. The skin incision is closed with wound clips
(Fig. 1Eb).
5. After surgery, the mouse is placed in lateral
recumbency in a clean, and warm cage.
6. The body weight of the mouse is measured and
recorded
7. Using a disposable 5 ml syringe, sterile saline
warmed by the heating pad (temperature: 35–37 °C)
is given by subcutaneous injection for hydration (1
ml per 25 g bodyweight).
8. The recovery cage is placed on a cage heating pad
to be warmed to 30–37 °C, and the mouse is
provided a means to move away from the heat
source once awake.
9. The mouse is maintained in the individually
ventilated cages (IVC) once it is able to walk
around the cage.
Protocol #7. Microscopic Morphology Observation of
Tumors
1. The mice were euthanized by 5% carbon dioxide
once it was observed that the bodyweight either
decreased or increased by more than 20% or if
abnormal physical symptoms occurred, such as
ascites or decline in motility.
2. Both stomach and metastatic tumors were detected
using a surgical microscope and pictures were
taken.
3. The tumor masses were collected and, using a
stainless steel tissue slicer matrix, a 1 mm thick slice
was generated for pathology procedures.
4. The slice was fixed with 10% neutral formalin for
24 h at 4 C°.
5. Tissue was embedded in paraffin, and Hematoxylin
& Eosin (H&E) staining was performed according
to standard protocols.
6. For immunohistochemistry (IHC), both the normal
stomach and the tumor were collected at 3 weeks
post-surgery then stained using the Ki-67 antibody.
7. The slide images were scanned using the
Hamamatsu NanoZoomer HT2.0 scanner, and
using NDPIView2 software, the microscopic
morphology was examined.
Materials
Fresh or cryopreserved gastric cancer patient or xeno-
graft tumor tissue.
Petri dish 100mm (Corning, 353,003).
Matrigel™ Basement Membrane Matrix (Corning,
354,234).
RPMI 1640 media (Gibco, 11,875,119).
18 gauge blunt needle (Weller Needles, KDS181P).
Sterile cotton swabs (Med Vet International,
CTA6STRLX10).
Invisishield Aperture Surgical Drape (Medline,
DYNJSD1020).
Sterile disposable drape (Medline, NON21001).
Disposable 1 ml syringe (Medline, B-D309628Z).
Disposable 5 ml syringe (Medline, B-D309646Z).
Disposable 31 gauge insulin syringe (BD, SY8290328289).
Gelfoam (Medline, 0009–0396-05).
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Tissue adhesive (B. Braun, Histoacryl).
Absorbable suture (Medline, ETHJ385H).
Autoclip kit and wound clips (Fine Science Tools, 12,
020–00).
50 ml falcon tube (Corning 352,098).
Mouse warmer (Stoelting, 53,850M).









Eight weeks-old, female NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ
(NSG) mouse (The Jackson Laboratory, #005557).
Surgical Instruments
Tissue preparation kit:
Dumont Forceps (Fine Science Tools, 11,251–35).
Single Edge Razor Blades (Electron Microscopy, 71,
970-WA).
Microsurgical kit:
Ring Forceps (Fine Science Tools, 11,103–09).
Dumont Forceps (Fine Science Tools, 11,251–35).
Micro-Blunted Tip Dumont Forceps (Fine Science
Tools, 11,253–25).
Moria Iris Forceps (Fine Science Tools, 11,373–12).
Extra Fine Graefe Forceps (Medline, MDS0757651).
Von Graefe Iris Forceps (Fine Science Tools, 11,051–10).
Iris scissors (Medline, MDS0805210).
Micro Needle Holders (Medline, MDS2442014).
Vannas Iridocapsulotomy Scissors (Fine Science Tools,
91,500–09).
Mouse retractor set (Fine Science Tools, 18,200–
20).
Dissection kits:
Von Graefe Iris Forceps (Fine Science Tools, 11,051–10),
Dumont Forceps (Fine Science Tools, 11,251–35).
Iris scissors (Medline, MDS0805210).
Single Edge Razor Blades (Electron Microscopy, 71,
970-WA).
Stainless steel tissue slicer matrix (Zivic, HSRS005–1).
Reagents
Topical anesthesia: bupivacaine HCl (0.1%) (Hospira,
Inc., NDC 0409–1159-18).
Puralube® Ophthalmic Ointment (Dechra Vet, NDC
17033–211-38).
70% ethanol (Fisher scientific, NC9663244).
Chlorhexidine (Durvet Inc., NDC 30798–668-35).
Phosphate-buffered saline (Gibco, 20,012,027).
10% neutral formalin (Fisher scientific, SF98–4).
Hematoxylin (Thermo scientific, 72,804).
Eosin (Leica, 3,801,600).
Ki-67 Antibody (Thermo Scientific, RM-9106).
Drug Concentration
Concentration of anesthetics 10mg/ml Ketamine
(Pfizer, 00409205105) plus 2 mg/ml Xylazine (Akorn, 59,
399–110-20) diluted with sterile saline.
Concentration of analgesics 1 mg/ml Ketoprofen
(Zoetis, 10,004,031) diluted with sterile saline.
Equipment
Surgical microscope assembled with the camera (Leica,
M156C).
BSL2 Biosafety cabinet.
IVC and cage racks.
Carbone dioxide rodent euthanasia system.
NanoZoomer slide scanner (Hamamatsu, HT2.0).
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IP: Intraperitoneal; IVC: Individually ventilated cages; H&E: Hematoxylin &
Eosin; IHC: Immunohistochemistry
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